Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Gynecology

Diagnosing Your Cyst: Imaging, Blood Tests, and Pathology

At a Glance

An ovarian cystadenoma is assessed using ultrasound, sometimes MRI, and blood tests such as CA-125, but these tests estimate risk rather than prove the diagnosis. Microscopic examination of tissue removed during surgery provides the definitive diagnosis.

Diagnosing an ovarian cystadenoma is a multi-step process. Because imaging alone cannot look at cells under a microscope, your care team uses a combination of specialized ultrasound, blood tests, and occasionally MRI to estimate the risk that a cyst is benign [1]. The only way to confirm a diagnosis with 100% certainty is through a histopathologic examination—analyzing the tissue after it has been surgically removed [2][1].

The Role of Imaging

Imaging is the first line of defense. Radiologists look for specific “reassuring” features that suggest a cyst is a benign cystadenoma rather than something more serious.

Ultrasound: The First Look

Ultrasound is the most common tool for evaluating ovarian cysts. To help doctors speak the same language, they use standardized risk-classification systems like IOTA (International Ovarian Tumor Analysis) or O-RADS (Ovarian-Adnexal Reporting and Data System) for ultrasound [3][4]. Remember that an O-RADS score is a risk category, not a final histologic diagnosis.

  • Reassuring Features: A suspected benign serous cystadenoma often appears as a unilocular cyst—a single, smooth-walled sac filled with clear fluid [5]. It should have no solid components (firm tissue) or mural nodules (bumps on the inside wall) [5].
  • The “Honeycomb” Appearance: A suspected mucinous cystadenoma is more likely to be multilocular, meaning it looks like a cluster of many small fluid-filled pockets separated by thin walls (septa) [6][7].
  • Concerning Features: Doctors become more concerned if they see papillary projections (small finger-like growths) that have their own blood flow, or if the cyst walls are thick and irregular [8][9]. If these are present, you may need a gynecologic-oncology assessment.

MRI: The “Problem Solver”

If an ultrasound is “indeterminate” (unclear), your doctor may order an MRI. MRI is excellent at identifying whether a structure inside a cyst is truly solid tissue or just thick fluid [10].

  • Stained-Glass Appearance: On MRI, mucinous cystadenomas often show a “stained-glass” pattern, where different pockets of the cyst have different colors because the fluid (mucin) inside them has different thicknesses [11].
  • O-RADS MRI Score: Radiologists also use an MRI version of the O-RADS scale (1 to 5). A score of 2 or 3 generally indicates a very low risk of malignancy, while scores of 4 or 5 require more intensive follow-up or surgical intervention [12].

Understanding Tumor Markers (CA-125)

You may be given a blood test for CA-125, a protein that can be elevated in the presence of ovarian cancer. However, it is a limited tool and must be interpreted carefully [2].

  • It is not a “Cancer Test”: CA-125 is not specific to cancer. It can be elevated by many benign conditions, including endometriosis, uterine fibroids, menstruation, or even a simple infection [2][13].
  • Context Matters: In one specific study cohort, about 89% of women with benign ovarian tumors had a normal CA-125 level (below 35 U/mL) [14]. However, this statistic alone does not rule cancer in or out.
  • When it’s Helpful: Doctors use CA-125 alongside your menopausal status and imaging to help calculate a “Risk of Malignancy Index” (RMI). It is more reliable in postmenopausal women, as premenopausal women have many more natural reasons for the protein to fluctuate [15].

Your Pathology Report

After surgery, a pathologist examines the cyst under a microscope. This integrated report is the “gold standard” for your diagnosis.

A benign report generally describes the overall architecture and cellular details of the cyst. While pathologists evaluate the whole picture rather than relying on a rigid checklist, examples of what they look for include:

Feature Examples of Reassuring Terminology Why it matters
Cell Lining “Single layer of columnar or cuboidal cells” [16][17] Confirms the cells are organized and not piling up excessively.
Atypia “Absence of cytologic atypia” [18] “Atypia” means the cells look abnormal or “angry”.
Invasion “No evidence of destructive stromal invasion” [19] This is crucial; it confirms the cells are not “eating into” the ovary tissue.
Complexity “Smooth lining” or “Simple architecture” Shows the cyst does not have the highly complex, branching patterns seen in borderline tumors [20].

Do Not Self-Diagnose: It is important not to self-interpret isolated words. Benign lesions can occasionally show some complex architecture or occasional mitoses. If your report uses terms like stratification (more than 2-3 layers of cells) or nuclear pleomorphism, these are features that might lean toward a borderline tumor rather than a simple benign cystadenoma, but they must be interpreted in context by your specialist [21]. Always ask your treating clinician to explain the final integrated diagnosis.

Common questions in this guide

Can an ultrasound confirm that an ovarian cyst is a cystadenoma?
Ultrasound can suggest a benign cystadenoma by showing features such as a smooth-walled, fluid-filled cyst without solid parts. It cannot examine cells under a microscope, so imaging alone cannot provide a certain final diagnosis.
What does an O-RADS score mean for an ovarian cyst?
O-RADS is a risk category based on ultrasound or MRI findings, not a final tissue diagnosis. Lower scores generally indicate lower risk of malignancy, while higher scores may lead to closer follow-up or gynecologic-oncology assessment.
Why might my doctor order an MRI after an ultrasound?
MRI may be recommended when an ultrasound is unclear. It can help distinguish solid tissue from thick fluid and may clarify features such as the stained-glass appearance sometimes seen in mucinous cystadenomas.
Does a high CA-125 level mean I have ovarian cancer?
No. CA-125 can rise with benign conditions such as endometriosis, fibroids, menstruation, or infection. Doctors interpret it with menopausal status and imaging; by itself, it cannot confirm or exclude cancer.
What confirms an ovarian cystadenoma diagnosis after surgery?
A pathologist examines the removed cyst under a microscope in a histopathologic examination. An organized cell lining, no cellular atypia, no destructive stromal invasion, and simple architecture can support a benign cystadenoma, but the final interpretation requires the complete report.
Which pathology terms might raise concern for a borderline ovarian tumor?
Terms such as stratification or nuclear pleomorphism may raise concern for a borderline tumor, but an isolated word does not establish a diagnosis. The pathologist and treating clinician interpret all microscopic findings together.

Get notified when new evidence is published on ovarian cystadenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Clinicomorphological Spectrum of Ovarian Cystic Lesions.

    Dhakal R, Makaju R, Bastakoti R

    Kathmandu University medical journal (KUMJ) 2016; (14(53)):13-16.

    PMID: 27892434
  2. 2

    Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

    Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2016; (26(1)):43-51 doi:10.1097/IGC.0000000000000586.

    PMID: 26588231
  3. 3

    Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.

    Timmerman D, Van Calster B, Testa A, et al.

    American journal of obstetrics and gynecology 2016; (214(4)):424-437 doi:10.1016/j.ajog.2016.01.007.

    PMID: 26800772
  4. 4

    External validation of ultrasound-based models for differentiating between benign and malignant adnexal masses: a nationwide prospective multicenter study (IOTA phase 6).

    Moro F, Momi M, Ledger A, et al.

    American journal of obstetrics and gynecology 2025; (233(6)):629.e1-629.e13 doi:10.1016/j.ajog.2025.07.017.

    PMID: 40653066
  5. 5

    Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice.

    Ohya A, Fujinaga Y

    Japanese journal of radiology 2022; (40(12)):1213-1234 doi:10.1007/s11604-022-01321-x.

    PMID: 35916971
  6. 6

    The Coexistence of Two Different Epithelial Ovarian Tumors: A Rare Case.

    Topaloğlu ÖF, Uysal E, Çelik ZE, Çelik Ç

    Current medical imaging 2022; (18(4)):421-424 doi:10.2174/1573405617666210908125237.

    PMID: 34503421
  7. 7

    A Nomogram Combined Radiomic and Semantic Features as Imaging Biomarker for Classification of Ovarian Cystadenomas.

    Pan S, Ding Z, Zhang L, et al.

    Frontiers in oncology 2020; (10()):895 doi:10.3389/fonc.2020.00895.

    PMID: 32547958
  8. 8

    Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses.

    Velayo CL, Reforma KN, Sicam RVG, et al.

    Healthcare (Basel, Switzerland) 2022; (11(1)) doi:10.3390/healthcare11010008.

    PMID: 36611467
  9. 9

    Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules.

    Abramowicz JS, Timmerman D

    American journal of obstetrics and gynecology 2017; (217(6)):652-660 doi:10.1016/j.ajog.2017.07.019.

    PMID: 28735703
  10. 10

    Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses.

    Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, et al.

    JAMA network open 2020; (3(1)):e1919896 doi:10.1001/jamanetworkopen.2019.19896.

    PMID: 31977064
  11. 11

    Postmenopausal adnexal torsion: rare case report.

    Abdelazim IA, AbuFaza M, Bekmukhambetov Y, et al.

    Przeglad menopauzalny = Menopause review 2020; (19(1)):49-51 doi:10.5114/pm.2020.95295.

    PMID: 32699544
  12. 12

    O-RADS MRI SCORE: An Essential First-Step Tool for the Characterization of Adnexal Masses.

    Thomassin-Naggara I, Dabi Y, Florin M, et al.

    Journal of magnetic resonance imaging : JMRI 2024; (59(3)):720-736 doi:10.1002/jmri.28947.

    PMID: 37550825
  13. 13

    Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.

    Dochez V, Caillon H, Vaucel E, et al.

    Journal of ovarian research 2019; (12(1)):28 doi:10.1186/s13048-019-0503-7.

    PMID: 30917847
  14. 14

    Clinicopathological Spectrum of Ovarian Tumors and Diagnostic Utility of Cancer Antigen 125 (CA-125): An Observational Study From Eastern India.

    Choudhary A, Paswan MK, Jamaiyar A

    Cureus 2026; (18(6)):e111404 doi:10.7759/cureus.111404.

    PMID: 42500789
  15. 15

    Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.

    Al Musalhi K, Al Kindi M, Al Aisary F, et al.

    Oman medical journal 2016; (31(5)):336-44 doi:10.5001/omj.2016.68.

    PMID: 27602187
  16. 16

    Giant Benign Ovarian Serous Cystadenoma in a Postmenopausal Woman.

    Mpourazanis G, Ntanasis A, Aliri M, et al.

    Cureus 2026; (18(5)):e108828 doi:10.7759/cureus.108828.

    PMID: 42291944
  17. 17

    Rare association of epidermoid cyst of ovary with mucinous cystadenoma- A Case Report.

    Qayoom Z, Yaqoob N

    JPMA. The Journal of the Pakistan Medical Association 2023; (73(5)):1108-1110 doi:10.47391/JPMA.5635.

    PMID: 37218245
  18. 18

    Pathology of borderline and invasive cancers.

    Prat J

    Best practice & research. Clinical obstetrics & gynaecology 2017; (41()):15-30 doi:10.1016/j.bpobgyn.2016.08.007.

    PMID: 28277307
  19. 19

    Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature.

    Wetterwald L, Sarivalasis A, Liapi A, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030890.

    PMID: 36765848
  20. 20

    MRI of Borderline Epithelial Ovarian Tumors: Pathologic Correlation and Diagnostic Challenges.

    Tsuboyama T, Sato K, Ota T, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(7)):2095-2111 doi:10.1148/rg.220068.

    PMID: 36083804
  21. 21

    Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

    Avril S

    Der Pathologe 2017; (38(Suppl 2)):180-191 doi:10.1007/s00292-017-0375-9.

    PMID: 29119232

This page explains how ovarian cystadenomas are evaluated for informational purposes only and does not constitute medical advice. Your gynecologist, radiologist, and pathologist should interpret your imaging, blood tests, and pathology together.